Stock listing

BOATS:STTK Shattuck Labs, Inc. Stock

US listing (BOATS) of Shattuck Labs, Inc. · home listing NASDAQ:STTK

Follow Shattuck Labs, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:STTK

$4.46 USD -0.01 (-0.2%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:STTK

Past year +131.1% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$4.42 – $4.68 USDNov 20, 2026
Volume
1.03M sharesNov 20, 2026
Market cap
$454.2M USDAt the close on Nov 20, 2026 · price × 101.8M shares outstanding
52-week range
$1.89 – $8.33 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$6.99M USDMedian day 956,600 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Shattuck Labs, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:STTK · Home$4.46 USD-0.01 (-0.2%)1,031,130$4.48$4.68$4.42$4.47Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:STTK · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$4.46-0.01-0.2%$4.48$4.68$4.421,031,130
$4.47-0.12-2.6%$4.58$4.775$4.3382,075,290
$4.59-0.07-1.5%$4.755$4.755$4.44785,679
$4.66+0.01+0.2%$4.61$4.82$4.521,337,963
$4.65-0.16-3.3%$4.79$4.831$4.50775,896
$4.81-0.24-4.8%$5.03$5.03$4.6951,315,891
$5.05+0.20+4.1%$4.89$5.095$4.86984,409
$4.85-0.14-2.8%$4.92$5.10$4.79734,966
$4.99+0.37+8.0%$4.70$5.05$4.5351,271,396
$4.62+0.13+2.9%$4.49$4.76$4.381,148,332
$4.49-0.66-12.8%$5.11$5.11$4.441,427,676
$5.15-0.32-5.9%$5.60$5.72$5.10870,574
$5.47+0.15+2.8%$5.38$5.56$5.24849,982
$5.32-0.24-4.3%$5.59$5.64$5.22651,578
$5.56-0.16-2.8%$5.67$5.74$5.36951,430
$5.72-0.085-1.5%$5.85$5.95$5.57676,326
$5.805+0.035+0.6%$5.72$5.94$5.65799,175
$5.77+0.23+4.2%$5.55$5.81$5.48699,500
$5.54+0.05+0.9%$5.53$5.68$5.46706,094
$5.49-0.11-2.0%$5.54$5.595$5.36700,500
$5.60+0.02+0.4%$5.56$5.715$5.431,220,800
$5.58-0.26-4.5%$5.85$6.00$5.571,198,100
$5.84+0.47+8.8%$5.39$5.87$5.311,555,700
$5.37-0.05-0.9%$5.51$5.69$5.37869,600
$5.42-0.11-2.0%$5.53$5.55$5.27648,500
$5.53+0.20+3.8%$5.35$5.59$5.30867,800
$5.33-0.16-2.9%$5.32$5.52$5.1931,202,900
$5.49-0.60-9.9%$6.06$6.09$5.471,576,800
$6.09+0.12+2.0%$6.09$6.21$5.851,024,500
$5.97+0.31+5.5%$5.65$6.02$5.541,049,400
$5.66+0.005+0.1%$5.56$5.885$5.422,486,600
$5.655-0.205-3.5%$5.76$5.825$5.5521,109,300
$5.86-0.64-9.8%$6.55$6.65$5.851,595,400
$6.50-0.23-3.4%$6.73$6.85$6.2951,239,400
$6.73-0.11-1.6%$7.02$7.09$6.541,843,600
$6.84+0.02+0.3%$6.95$7.285$6.672,022,300
$6.82+0.28+4.3%$6.64$7.42$6.523,356,700
$6.54+0.11+1.7%$6.43$6.635$6.32956,600
$6.43+0.36+5.9%$6.03$6.48$5.85976,900
$6.07-0.24-3.8%$6.33$6.387$6.045893,700
$6.31-0.05-0.8%$6.34$6.40$6.001,428,700
$6.36-0.14-2.2%$6.47$6.61$6.2651,386,500
$6.50+0.39+6.4%$6.20$6.54$6.101,459,300
$6.11+0.10+1.7%$6.09$6.21$5.861,037,100
$6.01+0.16+2.7%$5.86$6.215$5.807,400,000
$5.85-0.03-0.5%$6.03$6.095$5.80654,400
$5.88-0.09-1.5%$6.00$6.12$5.78742,700
$5.97-0.23-3.7%$6.18$6.23$5.911895,200
$6.200.000.0%$6.21$6.265$6.085821,900
$6.20+0.05+0.8%$6.24$6.36$6.07846,900
$6.15-0.18-2.8%$6.21$6.345$6.101,171,900
$6.33-0.17-2.6%$6.39$6.57$6.2451,062,000
$6.50-0.29-4.3%$6.80$6.86$6.471,002,700
$6.79-0.17-2.4%$6.84$6.88$6.674677,700
$6.96+0.05+0.7%$6.96$7.045$6.83563,900
$6.91+0.04+0.6%$6.91$7.28$6.77583,400
$6.87-0.14-2.0%$6.90$7.06$6.76639,600
$7.01-0.03-0.4%$6.98$7.04$6.83751,200
$7.04-0.61-8.0%$7.55$7.59$7.035623,100
$7.65-0.25-3.2%$7.86$7.93$7.63543,100
$7.90-0.16-2.0%$8.03$8.04$7.79581,600
$8.06+0.16+2.0%$8.01$8.15$7.93869,797
$7.90+0.37+4.9%$7.66$8.02$7.502,055,160
$7.53+0.28+3.9%$7.35$7.55$7.25475,600
$7.25-0.41-5.4%$7.56$7.56$7.24419,700
Ticker
BOATS:STTK
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
BOATS
Currency
USD

What changed lately

Latest news

All Shattuck Labs, Inc. news

Shattuck Labs, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
16 in the last 12 months · 81 in all · newest Nov 12, 2026 · oldest 2020
Calls
1 call with a replay · 1 with a transcript · latest Nov 9, 2023
Decks
6 decks · latest Jun 9, 2026

Where Shattuck Labs, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:STTK · Home listingNASDAQUnited StatesUSD
BOATS:STTK · This pageBOATSUnited StatesUSD

Valuation

Price/book 2.4× against a median of 2.2×: 6th lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$260.4M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
2.4×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.10

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Shattuck Labs, Inc. · NASDAQ:STTKUS$454.2MUS$260.4Mn/an/an/a2.4×n/a0.0×1.10
Monopar Therapeutics Inc. · NASDAQ:MNPRUS$467.6MUS$362.8Mn/an/an/a3.7×n/a0.0×1.18
BlossomHill Therapeutics, Inc. · NASDAQ:BLSMUS$461.2MUS$259.4Mn/an/an/a2.2×n/a0.1×n/a
Neurogene Inc. · NASDAQ:NGNEUS$458.5MUS$106.4Mn/an/an/a1.3×n/a0.0×1.47
Assembly Biosciences, Inc. · NASDAQ:ASMBUS$454.4MUS$142.3Mn/a2.1×n/a1.5×−16.6%0.0×1.00
G2GBIO, Inc. · KRX:456160US$449.1MUS$289.0Mn/a176×n/a4.3×−793.7%0.0×n/a
DiaMedica Therapeutics Inc. · NASDAQ:DMACUS$445.1MUS$410.4Mn/an/an/a15.5×n/a0.0×1.67
CytomX Therapeutics, Inc. · NASDAQ:CTMXUS$442.5MUS$98.96Mn/a7.0×n/a1.6×−609.0%0.0×1.21
Capricor Therapeutics, Inc. · NASDAQ:CAPRUS$441.3MUS$335.9Mn/an/an/a2.1×n/a0.4×0.94
Hansa Biopharma AB · OMXSTO:HNSAUS$440.9MUS$488.0Mn/a26.3×n/an/a−406.5%n/an/a
Shanghai MicuRx Pharmaceutical Co., Ltd. Class A · SSE:688373US$439.3MUS$408.1Mn/a16.2×n/a19.4×−57.0%0.9×n/a
Median of the othersUS$447.1MUS$312.5M16.2×2.2×−406.5%0.0×1.19

Forecasts

9 strong buy · 3 buy · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.

Price target
15.40 USD · Analysts' mean
EPS, year to Dec 2026
-0.55 · 11 analysts
Revenue, year to Dec 2026
122.2K · 9 analysts

Team and board

Officers

OfficerRole
Taylor H. SchreiberChief Executive Officer, and Co-founder
Andrew R. NeillChief Financial Officer
Clay SiegallPresident, Chairman of the Board of Immunome, Inc.
Stephen StoutGeneral Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
Amy FrankeVice President of Clinical Operations
Brad HuckabeeVice President of Accounting and SEC reporting
George GolumbeskiChairman of the Board and Former Executive Vice President of Business Development for Celgene
Kelli CollinSenior Vice President of Quality
Michael ChoiVice President of Clinical Development
Philip JacksonVice President of FP&A
Shoba RavichandranSenior Vice President of Clinical Development
Thomas LampkinSenior Vice President of Regulatory Affairs
Abhinav A. ShuklaChief Technical Officer
Casi DeYoungChief Business Officer
Lini PanditeChief Medical Officer
Suresh de SilvaChief Scientific Officer

Board

DirectorRole
George GolumbeskiChairman of the Board and Former Executive Vice President of Business Development for Celgene
Taylor H. SchreiberChief Executive Officer, and Co-founder

Events

Next results
Mar 11, 2027 (expected)

Calls

CallWhenStatus
Shattuck Labs (NASDAQ:STTK) Q3 2023 Earnings CallThu, Nov 09, 2023 · 8:00 AM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 5, 2026 · Before open−12.8%
Q2 2026Aug 11, 2026 · Before open+0.6%
Q1 2026May 7, 2026 · Before open−6.3%
Q4 2025Mar 17, 2026+0.3%
Q3 2025Nov 6, 2025 · After close+1.0%
Q2 2025Aug 14, 2025 · Before open+6.0%
Q1 2025Apr 30, 2025 · Before open+19.0%
Q4 2024Mar 27, 2025 · Before open−3.4%
Q3 2024Nov 14, 2024 · Before open+12.3%
Q2 2024Aug 1, 2024 · After close−3.2%
All 20 quarters
QuarterResultsShare move
Q1 2024May 2, 2024 · Before open+2.2%
Q4 2023Feb 29, 2024 · After close+10.5%
Q3 2023Nov 9, 2023 · Before open−23.2%
Q2 2023Aug 10, 2023 · After close−2.3%
Q1 2023May 9, 2023 · After close−2.1%
Q4 2022Feb 23, 2023 · After close+0.4%
Q3 2022Nov 8, 2022 · After close−5.9%
Q2 2022Aug 11, 2022 · Before open−4.4%
Q1 2022May 12, 2022 · Before open+8.3%
Q4 2021Mar 15, 2022 · Before open+3.3%

Open Events

Decks

DeckKindSlidesDate
Corporate Update (June 2026)Corporate update25 slidesJun 9, 2026
Investor Presentation (November 2025)Investor deck30 slidesNov 6, 2025
European Crohn's and Colitis Organization 2025Conference9 slidesFeb 20, 2025
3rd Gamma Delta T Therapy Summit 2022Conference28 slidesJul 27, 2022
TIGIT Therapies Digital Summit 2021Conference30 slidesDec 9, 2021
SITC 2021 Annual Meeting Investor Conference Call & WebcastConference44 slidesNov 12, 2021

Open Decks

Financings

RaiseDate
Public offering of shares of common stock and pre-funded warrants
Update: about US$75M · US$4 a share · Leerink Partners +3
Dealers: Leerink Partners (co-lead), J.P. Morgan (co-lead), Piper Sandler (co-lead), Cantor (co-lead)
Jun 10, 2026
Warrant exercise of common stock warrants
Announced: about US$54.9M
Jun 9, 2026
Private placement of common stock and common stock warrants
Closed: US$103M raised · US$0.8677 a share · Warrants at US$1.0846 · Wedbush & Co., LLC
Dealers: Wedbush & Co., LLC (lead)
Buyers: OrbiMed (led the private placement); Coastlands Capital; Prosight Capital; Adage Capital; Redmile Group; NextBio Capital
Use of proceeds: Fund operations into 2029 and advance SL-325 through clinical milestones, including randomized Phase 2 trials
Aug 26, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$17.00 a share on Oct 8, 2020.

Price
US$17.00 a share
Shares offered
11,882,352 shares of common stock
Offering size
US$202 million
Underwriters' option
Up to 1,782,352 more shares
Underwriters
Citigroup, Cowen, Evercore ISI, Needham & Company · In the order on the cover
Shares delivered
On or about Oct 14, 2020

Steps

StepWhen
Draft sent to the SEC in confidenceAug 7, 2020
Filed publiclySep 18, 2020
Amended twiceNewest Oct 8, 2020
Shares registered with an exchangeOct 5, 2020
Declared effective by the SECOct 8, 2020
Final prospectus, with the priceOct 13, 2020

Open IPO · From the cover of the final prospectus (424B4) filed Oct 13, 2020

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue1.00M5.72M1.66M652.0K30.0M9.93M9.89M22.4M
Cost of revenue2.95M4.89M4.04M3.38M1.38M37.5M29.2M24.8M
Gross profit-1.95M827.0K-2.38M652.0K28.6M9.93M-19.3M-2.37M
Research and development35.3M67.2M74.3M82.9M56.6M37.5M29.2M24.8M
Selling, general and administrative17.2M19.1M19.3M21.1M18.7M9.38M5.74M3.78M
Operating income-51.5M-80.6M-92.0M-103.3M-45.3M-36.9M-25.1M-6.15M
Depreciation and amortization3.70M3.80M4.00M3.10M1.40M600.0K500.0K255.0K
EBITDA-47.8M-76.8M-88.0M-100.2M-43.9M-36.3M-24.6M-5.89M
Interest expense3.07M1.38M002.63M
Income before tax-48.8M-75.4M-87.3M-101.9M-45.0M-36.6M-24.0M-7.39M
Income tax00000001.39M
Net income-48.8M-75.4M-87.3M-101.9M-45.0M-36.6M-24.0M-7.39M
Earnings per share, basic-0.70-1.49-2.05-2.41-1.07-2.36-3.17-0.49
Earnings per share, diluted-0.70-1.49-2.05-2.41-1.07-2.36-3.17

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash and equivalents54.2M57.4M125.6M47.4M92.3M157.9M7.01M31.6M
Short-term investments23.9M15.6M5.00M113.9M176.5M177.6M32.1M28.7M
Receivables3.07M381.0K2.60M
Current assets82.5M79.2M143.2M184.6M288.3M345.6M42.4M65.6M
Property, plant and equipment6.11M9.81M13.8M17.7M9.94M3.00M2.44M2.50M
Total assets91.0M91.0M159.6M205.3M298.6M349.0M45.0M68.2M
Accounts payable2.10M2.42M1.59M7.17M10.0M1.75M3.05M2.05M
Current liabilities7.05M8.92M11.5M25.0M24.6M16.8M20.0M20.9M
Total debt2.42M3.41M4.20M4.90M
Total liabilities8.64M11.4M14.9M29.2M26.8M39.1M30.5M79.2M
Shareholders' equity82.4M79.6M144.7M176.2M271.8M309.9M-34.5M-11.1M
Shares outstanding63.3M47.7M47.3M42.4M42.3M41.8M7.60M15.0M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations-39.9M-60.5M-81.2M-94.5M-57.1M-33.7M-21.0M-6.90M
Capital spending-71.0K-59.0K-407.0K-11.6M-7.93M-727.0K-470.0K-1.18M
Free cash flow-40.0M-60.6M-81.6M-106.1M-65.0M-34.4M-21.4M-8.08M
Cash from investing-7.89M-8.51M110.9M49.4M-10.4M-146.3M-3.59M-29.9M
Cash from financing44.6M787.0K48.6M171.0K1.93M330.9M-64.0K35.1M
Share buybacks-17.0K-53.0K171.0K1.93M213.2M
Change in cash-3.19M-68.2M78.2M-44.9M-65.6M150.9M-24.6M-1.68M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 5, 2026Quarterly reportSEC
8-K · Current reportNov 5, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeOct 27, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
S-8 · Registration statement for employee plansAug 11, 2026Offer documentSEC
8-K · Current reportAug 11, 2026ResultsSEC
10-Q · Quarterly reportAug 11, 2026Quarterly reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedJul 17, 2026Big-stake noticeSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipJul 7, 2026Insider tradeSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
144 · Notice of proposed saleJul 2, 2026Other filingsSEC
144 · Notice of proposed saleJul 1, 2026Other filingsSEC
144 · Notice of proposed saleJun 30, 2026Other filingsSEC
SCHEDULE 13G · Big-stake noticeJun 17, 2026Big-stake noticeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJun 15, 2026Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJun 11, 2026Big-stake noticeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
8-K · Current reportJun 11, 2026Material contractSEC
424B5 · ProspectusJun 11, 2026Offer documentSEC
4 · Change in ownershipJun 9, 2026Insider tradeSEC
4 · Change in ownershipJun 9, 2026Insider tradeSEC
424B5 · ProspectusJun 9, 2026Offer documentSEC
8-K · Current reportJun 9, 2026Current reportSEC
4 · Change in ownershipJun 2, 2026Insider tradeSEC
4 · Change in ownershipJun 2, 2026Insider tradeSEC
4 · Change in ownershipJun 2, 2026Insider tradeSEC
4 · Change in ownershipJun 2, 2026Insider tradeSEC
4 · Change in ownershipJun 2, 2026Insider tradeSEC
4 · Change in ownershipJun 2, 2026Insider tradeSEC
8-K · Current reportJun 2, 2026Management or board changeSEC
4 · Change in ownershipMay 27, 2026Insider tradeSEC
4 · Change in ownershipMay 21, 2026Insider tradeSEC
4 · Change in ownershipMay 18, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
4 · Change in ownershipMay 14, 2026Insider tradeSEC
4 · Change in ownershipMay 14, 2026Insider tradeSEC
4 · Change in ownershipMay 14, 2026Insider tradeSEC
4 · Change in ownershipMay 13, 2026Insider tradeSEC
4 · Change in ownershipMay 12, 2026Insider tradeSEC
144 · Notice of proposed saleMay 12, 2026Other filingsSEC
144 · Notice of proposed saleMay 12, 2026Other filingsSEC
10-Q · Quarterly reportMay 7, 2026Quarterly reportSEC
8-K · Current reportMay 7, 2026ResultsSEC
ARS · Annual report to shareholdersApr 8, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 8, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 8, 2026Meeting noticeSEC
10-K · Annual reportMar 5, 2026Annual reportSEC
8-K · Current reportMar 5, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeFeb 6, 2026Big-stake noticeSEC
8-K · Current reportFeb 5, 2026Current reportSEC
4 · Change in ownershipJan 27, 2026Insider tradeSEC
4 · Change in ownershipJan 27, 2026Insider tradeSEC
4 · Change in ownershipJan 27, 2026Insider tradeSEC
4 · Change in ownershipJan 27, 2026Insider tradeSEC
8-K · Current reportJan 22, 2026Material contractSEC
424B5 · ProspectusJan 22, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveJan 22, 2026Other filingsSEC
CORRESP · Letter to the SECJan 16, 2026Other filingsSEC
UPLOAD · Letter from the SECJan 16, 2026Other filingsSEC
4 · Change in ownershipJan 13, 2026Insider tradeSEC
4 · Change in ownershipJan 13, 2026Insider tradeSEC
4 · Change in ownershipJan 13, 2026Insider tradeSEC
4 · Change in ownershipJan 13, 2026Insider tradeSEC
4 · Change in ownershipJan 13, 2026Insider tradeSEC
4 · Change in ownershipJan 13, 2026Insider tradeSEC
S-3 · Registration statementJan 13, 2026Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 13, 2025Big-stake noticeSEC
8-K/A · Current report, amendedNov 6, 2025ResultsSEC
10-Q · Quarterly reportNov 6, 2025Quarterly reportSEC
8-K · Current reportNov 6, 2025ResultsSEC
424B3 · ProspectusSep 29, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveSep 29, 2025Other filingsSEC
CORRESP · Letter to the SECSep 24, 2025Other filingsSEC
UPLOAD · Letter from the SECSep 24, 2025Other filingsSEC
S-3 · Registration statementSep 18, 2025Offer documentSEC
SCHEDULE 13D · Big-stake noticeSep 2, 2025Big-stake noticeSEC
4 · Change in ownershipSep 2, 2025Insider tradeSEC
4 · Change in ownershipSep 2, 2025Insider tradeSEC
3 · Initial statement of ownershipSep 2, 2025Insider tradeSEC
4 · Change in ownershipSep 2, 2025Insider tradeSEC
4 · Change in ownershipSep 2, 2025Insider tradeSEC
3 · Initial statement of ownershipSep 2, 2025Insider tradeSEC
3 · Initial statement of ownershipSep 2, 2025Insider tradeSEC
4 · Change in ownershipAug 27, 2025Insider tradeSEC
4 · Change in ownershipAug 27, 2025Insider tradeSEC
4 · Change in ownershipAug 27, 2025Insider tradeSEC
4 · Change in ownershipAug 27, 2025Insider tradeSEC
4 · Change in ownershipAug 27, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedAug 26, 2025Big-stake noticeSEC
4 · Change in ownershipAug 26, 2025Insider tradeSEC
8-K · Current reportAug 26, 2025Management or board changeSEC
10-Q · Quarterly reportAug 14, 2025Quarterly reportSEC
8-K · Current reportAug 14, 2025ResultsSEC
SCHEDULE 13D/A · Big-stake notice, amendedAug 6, 2025Big-stake noticeSEC
8-K · Current reportAug 5, 2025Material contractSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 29, 2025Big-stake noticeSEC
4 · Change in ownershipJul 16, 2025Insider tradeSEC
4 · Change in ownershipJul 16, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 16, 2025Big-stake noticeSEC
4 · Change in ownershipJul 16, 2025Insider tradeSEC
4 · Change in ownershipJul 16, 2025Insider tradeSEC
4 · Change in ownershipJul 16, 2025Insider tradeSEC
4 · Change in ownershipJul 16, 2025Insider tradeSEC
4 · Change in ownershipJul 16, 2025Insider tradeSEC
4 · Change in ownershipJul 16, 2025Insider tradeSEC
4 · Change in ownershipJul 16, 2025Insider tradeSEC
8-K · Current reportJul 15, 2025Meeting outcomeSEC
ARS · Annual report to shareholdersMay 21, 2025Annual reportSEC
DEFA14A · Additional proxy materialMay 21, 2025Meeting noticeSEC
DEF 14A · Proxy statementMay 21, 2025Meeting noticeSEC
10-Q · Quarterly reportMay 1, 2025Quarterly reportSEC
8-K · Current reportMay 1, 2025ResultsSEC
10-K/A · Annual report, amendedMay 1, 2025Annual reportSEC
10-K/A · Annual report, amendedApr 30, 2025Annual reportSEC
424B5 · ProspectusMar 27, 2025Offer documentSEC
S-8 · Registration statement for employee plansMar 27, 2025Offer documentSEC
10-K · Annual reportMar 27, 2025Annual reportSEC
8-K · Current reportMar 27, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 12, 2025Big-stake noticeSEC
4 · Change in ownershipJan 28, 2025Insider tradeSEC
4 · Change in ownershipJan 28, 2025Insider tradeSEC
4 · Change in ownershipJan 28, 2025Insider tradeSEC
4 · Change in ownershipJan 28, 2025Insider tradeSEC
4 · Change in ownershipJan 28, 2025Insider tradeSEC
4 · Change in ownershipJan 28, 2025Insider tradeSEC
4 · Change in ownershipJan 13, 2025Insider tradeSEC
4 · Change in ownershipJan 13, 2025Insider tradeSEC
4 · Change in ownershipJan 13, 2025Insider tradeSEC
SC 13D/A · Big-stake notice, amendedDec 6, 2024Big-stake noticeSEC
4 · Change in ownershipDec 6, 2024Insider tradeSEC
144 · Notice of proposed saleDec 4, 2024Other filingsSEC
10-Q · Quarterly reportNov 14, 2024Quarterly reportSEC
8-K · Current reportNov 14, 2024ResultsSEC
SC 13G/A · Big-stake notice, amendedNov 13, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 8, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 7, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 4, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeOct 24, 2024Big-stake noticeSEC
4 · Change in ownershipOct 8, 2024Insider tradeSEC
8-K · Current reportOct 1, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedAug 16, 2024Big-stake noticeSEC
10-Q · Quarterly reportAug 1, 2024Quarterly reportSEC
8-K · Current reportAug 1, 2024ResultsSEC
4 · Change in ownershipJul 1, 2024Insider tradeSEC
4 · Change in ownershipJun 26, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
8-K · Current reportJun 14, 2024Current reportSEC
8-K/A · Current report, amendedJun 11, 2024Management or board changeSEC
8-K · Current reportJun 10, 2024Meeting outcomeSEC
4 · Change in ownershipJun 5, 2024Insider tradeSEC
4 · Change in ownershipMay 14, 2024Insider tradeSEC
10-Q · Quarterly reportMay 2, 2024Quarterly reportSEC
8-K · Current reportMay 2, 2024ResultsSEC
ARS · Annual report to shareholdersApr 23, 2024Annual reportSEC
DEFA14A · Additional proxy materialApr 23, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 23, 2024Meeting noticeSEC
4 · Change in ownershipApr 1, 2024Insider tradeSEC
4 · Change in ownershipMar 8, 2024Insider tradeSEC
4 · Change in ownershipMar 8, 2024Insider tradeSEC
4 · Change in ownershipMar 8, 2024Insider tradeSEC
3 · Initial statement of ownershipMar 8, 2024Insider tradeSEC
3 · Initial statement of ownershipMar 8, 2024Insider tradeSEC
144 · Notice of proposed saleMar 6, 2024Other filingsSEC
8-K · Current reportMar 4, 2024Management or board changeSEC
S-8 · Registration statement for employee plansFeb 29, 2024Offer documentSEC
10-K · Annual reportFeb 29, 2024Annual reportSEC
8-K · Current reportFeb 29, 2024ResultsSEC
8-K · Current reportFeb 13, 2024Material contractSEC
SC 13G/A · Big-stake notice, amendedFeb 9, 2024Big-stake noticeSEC
424B3 · ProspectusFeb 2, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveFeb 1, 2024Other filingsSEC
4 · Change in ownershipJan 31, 2024Insider tradeSEC
4 · Change in ownershipJan 31, 2024Insider tradeSEC
4 · Change in ownershipJan 31, 2024Insider tradeSEC
4 · Change in ownershipJan 31, 2024Insider tradeSEC
CORRESP · Letter to the SECJan 30, 2024Other filingsSEC
UPLOAD · Letter from the SECJan 30, 2024Other filingsSEC
SC 13G · Big-stake noticeJan 29, 2024Big-stake noticeSEC
S-3 · Registration statementJan 24, 2024Offer documentSEC
4 · Change in ownershipJan 16, 2024Insider tradeSEC
4 · Change in ownershipJan 16, 2024Insider tradeSEC
4 · Change in ownershipJan 16, 2024Insider tradeSEC
4 · Change in ownershipJan 16, 2024Insider tradeSEC
4 · Change in ownershipJan 16, 2024Insider tradeSEC
4 · Change in ownershipJan 16, 2024Insider tradeSEC
144 · Notice of proposed saleJan 10, 2024Other filingsSEC

This page holds 200 of 415 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Shattuck Labs, Inc.’s releases · as of Nov 10, 2026

Common shares
101,842,552
Fully diluted
102,226,552

Fully diluted

LineSharesAs of
Common shares101,842,552Nov 2, 2026
Options and RSUs384,000Nov 10, 2026

Warrants and options

Lot
Warrants · US$1.08 · expiry not stated
Stock options · US$4.85 · expire about Nov 2036

Share count over time

CountShares
Nov 2, 2026101,842,552

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
T. Rowe Price17.4M17.1%US$119MSep 30, 2026
Prosight Management, LP7.65M7.5%US$52.2MSep 30, 2026
Adage Capital Partners Gp, L.L.C.7.14M7.0%US$48.7MSep 30, 2026
Orbimed Advisors LLC6.31M6.2%US$43MSep 30, 2026
BlackRock5.49M5.4%US$37.5MSep 30, 2026
Vanguard5.33M5.2%US$36.4MSep 30, 2026
Redmile Group, LLC5.09M5.0%US$34.7MSep 30, 2026
Frazier Life Sciences Management, L.P.3.75M3.7%US$25.6MSep 30, 2026
NEXTBio Capital Management LP3.73M3.7%US$25.4MSep 30, 2026
Deep Track Capital, LP3.71M3.6%US$25.3MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
State Street3.44M3.4%US$23.4MSep 30, 2026
Pinnacle Associates LTD2.1M2.1%US$14.3MSep 30, 2026
Geode Capital1.98M1.9%US$13.5MSep 30, 2026
Citadel1.72M1.7%US$11.7MSep 30, 2026
Clark Estates Inc1.42M1.4%US$9.66MSep 30, 2026
Point72 Asset Management, L.P.1.33M1.3%US$9.06MSep 30, 2026
Goldman Sachs1.27M1.3%US$8.68MSep 30, 2026
Boxer Capital Management, LLC1.18M1.2%US$8.02MSep 30, 2026
683 Capital Management, LLC920K0.90%US$6.27MSep 30, 2026
abrdn755K0.74%US$5.15MSep 30, 2026
Northern Trust677K0.66%US$4.62MSep 30, 2026
TD631K0.62%US$4.13MSep 30, 2026
Ally Bridge Group (NY) LLC625K0.61%US$4.26MSep 30, 2026
Connor, Clark & Lunn Investment Management Ltd.460K0.45%US$3.13MSep 30, 2026
Fidelity458K0.45%US$3.13MSep 30, 2026
Two Sigma443K0.43%US$3.02MSep 30, 2026
S&G Foundation436K0.43%US$2.97MSep 30, 2026
DWS366K0.36%US$2.49MSep 30, 2026
Renaissance Technologies287K0.28%US$1.95MSep 30, 2026
BNY266K0.26%US$1.81MSep 30, 2026
AQR Capital Management LLC255K0.25%US$1.74MSep 30, 2026
UBS250K0.25%US$1.7MSep 30, 2026
Schwab240K0.24%US$1.63MSep 30, 2026
Manufacturers Life Insurance Company, The237K0.23%US$1.62MSep 30, 2026
Morgan Stanley223K0.22%US$1.52MSep 30, 2026
Wellington218K0.21%US$1.49MSep 30, 2026
Hillsdale Investment Management Inc.195K0.19%US$1.33MSep 30, 2026
West Tower Group, LLC192K0.19%US$1.31MSep 30, 2026
Bank of America191K0.19%US$1.31MSep 30, 2026
Squarepoint Ops LLC174K0.17%US$1.19MSep 30, 2026
Dimensional156K0.15%US$1.06MSep 30, 2026
Millennium127K0.12%US$867KSep 30, 2026
Nuveen122K0.12%US$835KSep 30, 2026
Franklin Templeton117K0.11%US$603KSep 30, 2026
Raymond James Financial Inc88,4300.09%US$603KSep 30, 2026
Fisher Asset Management, LLC84,3060.08%US$575KSep 30, 2026
Invesco84,3040.08%US$575KSep 30, 2026
LBJ Family Wealth Advisors, Ltd.82,1770.08%US$560KSep 30, 2026
Rhumbline Advisers80,6800.08%US$550KSep 30, 2026
Rafferty Asset Management, LLC79,5350.08%US$542KSep 30, 2026

This page holds 50 of 112 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
T. Rowe Price Small-Cap Value Fund, Inc.3.57M3.5%US$24.7MJun 30, 2026
T. Rowe Price Small-Cap Stock Fund, Inc.3.11M3.1%US$21.6MJun 30, 2026
Vanguard Total Stock Market Index Fund2.37M2.3%US$16.4MJun 30, 2026
T. Rowe Price Health Sciences Fund, Inc.1.99M2.0%US$13.8MJun 30, 2026
T. Rowe Price Institutional Small-Cap Stock Fund1.68M1.6%US$11.6MJun 30, 2026
iShares Russell 2000 ETF1.54M1.5%US$10.7MJun 30, 2026
Vanguard Extended Market Index Fund768K0.75%US$5.33MJun 30, 2026
Fidelity Small Cap Index Fund672K0.66%US$4.75MJul 31, 2026
iShares Russell 2000 Growth ETF502K0.49%US$3.48MJun 30, 2026
Select Biotechnology Portfolio392K0.38%US$2.33MMay 31, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Vanguard Explorer Fund320K0.31%US$2.26MJul 31, 2026
Fidelity Extended Market Index Fund284K0.28%US$1.69MMay 31, 2026
iShares Micro-Cap ETF206K0.20%US$1.43MJun 30, 2026
Small Cap Value Portfolio204K0.20%US$1.41MJun 30, 2026
North Square Dynamic Small Cap Fund201K0.20%US$1.19MMay 31, 2026
Schwab Small-Cap Index Fund149K0.15%US$1.05MJul 31, 2026
SIMT Tax-Managed Small/Mid Cap Fund145K0.14%US$1.01MJun 30, 2026
T. Rowe Price Health Sciences Portfolio137K0.13%US$950KJun 30, 2026
Master Small Cap Index Series115K0.11%US$796KJun 30, 2026
Small Cap Equity Fund101K0.10%US$700KJun 30, 2026
Fidelity Total Market Index Fund99,1370.10%US$590KMay 31, 2026
Fidelity Series Total Market Index Fund83,9690.08%US$500KMay 31, 2026
Nuveen Small Cap Blend Index Fund81,4220.08%US$576KJul 31, 2026
T. Rowe Price Spectrum Moderate Growth Allocation Fund68,2300.07%US$406KMay 31, 2026
EQ/2000 Managed Volatility Portfolio66,5480.07%US$462KJun 30, 2026
iShares Russell 2000 Value ETF58,0280.06%US$403KJun 30, 2026
Siit Small Cap II Fund56,7000.06%US$337KMay 31, 2026
Small Company Growth Portfolio51,1790.05%US$355KJun 30, 2026
Small Company Value Trust51,0660.05%US$354KJun 30, 2026
Fidelity Small Cap Growth Index Fund50,0510.05%US$347KJun 30, 2026
Dimensional U.S. Small Cap ETF49,6230.05%US$351KJul 31, 2026
Avantis U.S. Small Cap Equity ETF48,4850.05%US$288KMay 31, 2026
LVIP State Street Small-Cap Index Fund44,6000.04%US$310KJun 30, 2026
Fidelity Nasdaq Composite Index Fund43,8340.04%US$261KMay 31, 2026
Ultra-Small Company Market Fund42,3000.04%US$294KJun 30, 2026
Schwab Total Stock Market Index Fund40,8810.04%US$289KJul 31, 2026
Vanguard Balanced Index Fund40,4390.04%US$281KJun 30, 2026
Health Sciences Trust39,7490.04%US$276KJun 30, 2026
Vanguard Institutional Total Stock Market Index Fund32,8220.03%US$228KJun 30, 2026
Invesco RAFI US 1500 Small-Mid ETF31,9810.03%US$226KJul 31, 2026
Small Cap Index Fund31,5840.03%US$219KJun 30, 2026
Global X Russell 2000 ETF29,1820.03%US$206KJul 31, 2026
EQ/T.Rowe Price Health Sciences Portfolio28,5100.03%US$198KJun 30, 2026
T. Rowe Price Health Care ETF25,3480.02%US$176KJun 30, 2026
T. Rowe Price Spectrum Moderate Allocation Fund24,6910.02%US$147KMay 31, 2026
ATM Small Cap Managed Volatility Portfolio23,2760.02%US$162KJun 30, 2026
State Street Small/Mid Cap Equity Index Portfolio21,3000.02%US$148KJun 30, 2026
MetLife Russell 2000 Index Portfolio21,2090.02%US$147KJun 30, 2026
Invesco NASDAQ Future Gen 200 ETF19,6820.02%US$117KMay 31, 2026
Small-Cap Index Portfolio17,6490.02%US$122KJun 30, 2026

This page holds 50 of 105 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Shukla Abhinav A.
Officer: Chief Technical Officer
Sale410USD 7.01US$2,874Jul 2, 2026
Shukla Abhinav A.
Officer: Chief Technical Officer
Sale100USD 7.07US$707Jul 1, 2026
Pandite Arundathy N.
Officer: Chief Medical Officer
Sale30,000USD 7.01US$210KJun 30, 2026
Shukla Abhinav A.
Officer: Chief Technical Officer
Sale23,365USD 7.08US$165KJun 30, 2026
Siegall Clay B
Director
Buy62,500USD 4.00US$250KJun 9, 2026
Pandite Arundathy N.
Officer: Chief Medical Officer
Sale30,000USD 6.61US$198KMay 12, 2026
Shukla Abhinav A.
Officer: Chief Technical Officer
Sale2,032USD 7.01US$14,244May 12, 2026

Big stakes

StakeStakeSharesDateFiling
T. Rowe Price Investment Management, Inc.14.30%14.3MSep 30, 2026Schedule 13G
Orbimed Advisors LLC9.99%9.02MJun 11, 2026Schedule 13D
Redmile Group, LLC9.90%10MJul 15, 2026Schedule 13D
Prosight Management, LP9.90%6.54MSep 30, 2025Schedule 13G
Adage Capital Partners Gp, L.L.C.9.79%4.67MDec 31, 2024Schedule 13G
BlackRock, Inc.5.30%5.34MSep 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Jeremy Green
Other companies: Atara Biotherapeutics, Inc. (Director · Since at least May 16, 2025); Fate Therapeutics, Inc. (Director · Since at least Dec 15, 2017); LifeSci Acquisition II Corp (Director · Oct 6, 2021 – May 11, 2023 · Past); Absci Corporation (Director · Jul 21, 2021 – Jun 12, 2024 · Past); Medavail Holdings Inc (Director · Nov 17, 2020 – Jun 16, 2023 · Past); Augmedix Inc (Director · Oct 5, 2020 – Oct 2, 2024 · Past); IGM Biosciences Inc (Director · Sep 17, 2019 – Mar 31, 2025 · Past); Alder BioPharmaceuticals Inc (Director · Apr 25, 2018 – Oct 22, 2019 · Past)
Director · Since at least Oct 8, 2020
Clay Siegall
Other companies: Tourmaline Bio Inc. (Director · Since at least Dec 13, 2023); Immunome, Inc. (President & Chief Executive Officer · Since at least Oct 2, 2023); Nurix Therapeutics, Inc. (Director · May 28, 2021 – May 5, 2022 · Past); Synlogic Inc (Director · Sep 30, 2015 – Jun 29, 2016 · Past); Alder BioPharmaceuticals Inc (Director · May 7, 2014 – Oct 22, 2019 · Past); Ultragenyx Pharmaceutical Inc. (Director · Jan 30, 2014 – Aug 7, 2020 · Past); Seagen Inc (President & CEO, Director · Jan 31, 2006 – May 12, 2022 · Past)
President, Chairman of the Board of Immunome, Inc. · Since at least Mar 1, 2024
George Golumbeski
Other companies: Acumen Pharmaceuticals, Inc. (Chairman of its Board of Directors · Since at least Nov 6, 2025); Mural Oncology plc (Director · Since at least Jul 30, 2024); Sage Therapeutics Inc (Director · Since at least Jan 22, 2019); Corbus Pharmaceuticals Holdings, Inc. (Director · Jul 6, 2020 – Jul 6, 2020 · Past); Enanta Pharmaceuticals, Inc. (Director · Feb 7, 2014 – Feb 26, 2020 · Past); Acceleron Pharma Inc (Director · Sep 18, 2013 – Sep 18, 2013 · Past)
Director · Since at least Oct 8, 2020
Helen M. Boudreau
Other companies: Rallybio Corporation (Board Member · Since at least Jul 29, 2021); Tvardi Therapeutics, Inc. (Director · Aug 2, 2023 – Jun 4, 2024 · Past); Kineta Inc. (Chief Financial Officer · Feb 10, 2016 – Mar 1, 2018 · Past)
Director · Since at least Oct 8, 2020
Neil Gibson
Other companies: Instil Bio, Inc. (Board Member · Since at least Mar 18, 2021); Tcr2 Therapeutics Inc (Director · Feb 13, 2019 – Jun 1, 2023 · Past); Regulus Therapeutics Inc (Chief Scientific Officer · Oct 4, 2012 – Jan 28, 2015 · Past)
Director · Since at least Oct 8, 2020
Daniel Baker
Other companies: Artiva Biotherapeutics, Inc. (Director · Since at least Jan 28, 2025); Cue Biopharma, Inc. (CHIEF DEVELOPMENT OFFICER · Since at least Nov 25, 2024)
Director · Since at least Aug 25, 2025
Michael Lee
Other companies: IGM Biosciences Inc (Director · Since at least Sep 17, 2019); Fate Therapeutics, Inc. (Board Member · Since at least Jul 31, 2018)
Director · Since at least Oct 8, 2020
Mona Ashiya
Other companies: Disc Medicine, Inc. (Director · Since at least Dec 29, 2022); Sierra Oncology Inc (Director · Jun 8, 2021 – Jul 1, 2022 · Past)
Director · Since at least Aug 25, 2025
Arundathy N Pandite
Other companies: Codiak BioSciences Inc (Director · Aug 16, 2021 – Jun 17, 2022 · Past)
Chief Medical Officer · Since at least Oct 8, 2020
Carrie Brownstein
Other companies: Zentalis Pharmaceuticals, Inc. (Chief Medical Officer · Oct 3, 2022 – Oct 4, 2023 · Past)
Director · Since at least Oct 22, 2021
All 29 people
PersonSeat
Casi DeYoung
Other companies: Synlogic Inc (Chief Business Officer · Sep 30, 2015 – Mar 11, 2016 · Past)
Chief Business Officer · Since at least Oct 8, 2020
Abhinav A. ShuklaChief Technical Officer · Since at least Apr 7, 2022
Amy FrankeVice President of Clinical Operations · Since at least Nov 4, 2026
Amy Kate SasserDirector · Since at least Mar 1, 2024
Andrew R. NeillChief Financial Officer · Since at least Oct 8, 2020
Brad HuckabeeVice President of Accounting and SEC reporting · Since at least Nov 4, 2026
Erin Ator ThomsonGeneral Counsel · Oct 8, 2020 – Jan 25, 2023 · Past
Josiah HornblowerDirector · Oct 8, 2020 – Jul 15, 2021 · Past
Kelli CollinSenior Vice President of Quality · Since at least Nov 4, 2026
Lini PanditeChief Medical Officer · Since at least Jun 5, 2026
Michael ChoiVice President of Clinical Development · Since at least Jun 5, 2026
Philip JacksonVice President of FP&A · Since at least Nov 4, 2026
Shoba RavichandranSenior Vice President of Clinical Development · Since at least Oct 1, 2026
Stephen StoutGeneral Counsel, Corporate Secretary and Chief Ethics and Compliance Officer · Since at least Mar 23, 2023
Suresh de SilvaChief Scientific Officer · Since at least Oct 13, 2026
Taylor H. SchreiberChief Executive Officer, and Co-founder · Since at least Oct 8, 2020
Thomas LampkinSenior Vice President of Regulatory Affairs · Since at least Nov 4, 2026
Tyler BrousDirector · Since at least Oct 8, 2020
Victor StoneDirector · Oct 8, 2020 – Oct 8, 2020 · Past

Open People

Log in to ask 6ix AI your own questions about Shattuck Labs, Inc.